140 related articles for article (PubMed ID: 31166063)
21. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
22. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G
J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458
[TBL] [Abstract][Full Text] [Related]
23. A pH-sensitive T7 peptide-decorated liposome system for HER2 inhibitor extracellular delivery: an application for the efficient suppression of HER2+ breast cancer.
Zhang S; Sun Q; Peng X; Gan N; Zhao L; Suo Z; Zhao G; Li H
J Mater Chem B; 2021 Nov; 9(42):8768-8778. PubMed ID: 34585713
[TBL] [Abstract][Full Text] [Related]
24. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
25. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells.
Chu B; Liu F; Li L; Ding C; Chen K; Sun Q; Shen Z; Tan Y; Tan C; Jiang Y
Cell Death Dis; 2015 Mar; 6(3):e1686. PubMed ID: 25766325
[TBL] [Abstract][Full Text] [Related]
26. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
27. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
28. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
29. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
30. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY
Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969
[TBL] [Abstract][Full Text] [Related]
31. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
32. Blockage of conformational changes of heat shock protein gp96 on cell membrane by a α-helix peptide inhibits HER2 dimerization and signaling in breast cancer.
Li X; Wang B; Liu W; Gui M; Peng Z; Meng S
PLoS One; 2015; 10(4):e0124647. PubMed ID: 25898135
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
34. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K
Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
36. A Multi-action Pt
Kostrhunova H; Zajac J; Markova L; Brabec V; Kasparkova J
Angew Chem Int Ed Engl; 2020 Nov; 59(47):21157-21162. PubMed ID: 32750194
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
38. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
39. Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.
Menendez JA; Schroeder B; Peirce SK; Vellon L; Papadimitropoulou A; Espinoza I; Lupu R
J Natl Cancer Inst; 2015 Jun; 107(6):djv090. PubMed ID: 25888715
[TBL] [Abstract][Full Text] [Related]
40. Treating the HER2 pathway in early and advanced breast cancer.
Pegram MD
Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
